Emergent BioSolutions Inc. (NYSE:EBS) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough

Simply Wall StApr 12 08:39 ET

AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."

① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.

cls.cnApr 11 07:59 ET

SA Asks: How Will Changes at FDA Impact Vaccine Makers?

Seeking AlphaApr 2 14:56 ET

Emergent Biosolutions: Strategic Share Repurchase and Diversified Revenue Streams Signal Strong Buy Opportunity

TipRanksApr 1 06:25 ET

Emergent BioSolutions Announces $50M Stock Repurchase Program

TipRanksMar 31 08:10 ET

Express News | Emergent BioSolutions Inc - Authorizes $50 Million Stock Repurchase Program

ReutersMar 31 08:00 ET